Compensation award — excluded from discretionary-purchase analysis.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
View the official recordSEC Form 4 — Statement of Changes in Beneficial OwnershipAll the details
Dates, kept separate
Transaction date
Mar 8, 2026
Reporting period
Not applicable
Filed with the SEC
Mar 10, 2026
CEOGrant / award
Context
Classification
grant award
Code A — grant or award
Planned / mechanical clue
Footnote references vesting of compensation awards
Only flagged when a footnote says so; never inferred
Source receipt
Record ID
0001093557-26-000046
Filed / recorded
Mar 10, 2026, 8:01 PM UTC
Added to OQRO
Oct 2, 2026, 12:27 PM UTC
Parser
form4-xml-v1
Data quality
Verified: identifiers matched exactly
Issuer
DEXCOM INC
Issuer CIK
1093557
Ticker
DXCM
Reporting person
Jacob Steven Leach
Relationship
Director, Officer
Officer title
President, CEO, and Director
Security
Common Stock
Table
Non-derivative (Table I)
Transaction date
Mar 8, 2026
Transaction code
A
Shares / units
104,516
Price per share
$0.00
Acquired / disposed
Acquired (A)
Shares owned after
441,567
Ownership form
Direct
Amendment
No
Footnotes from the filing
Represents a grant of restricted stock units (RSUs) that are exempt from Section 16b-3 and are subject to vesting in three equal annual installments from the date of grant. RSUs represent a contingent right to receive one share of DexCom, Inc. Common Stock.